Predict your next investment

Vitrolife company logo
Corporation
HEALTHCARE | Biotechnology
vitrolife.com

See what CB Insights has to offer

Investments

2

Portfolio Exits

1

Partners & Customers

2

Service Providers

3

About Vitrolife

Vitrolife is a global biotechnology/medical device Group that works in the areas of fertility and transplantation. The fertility product area works with nutrient solutions (media), cryopreservation products, and advanced consumable instruments, such as needles and pipettes, for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. The transplantation product area works with solutions and systems for assessing and preserving organs outside the body, so as to be able to select usable organs and keep them in optimal condition pending transplantation.

Vitrolife Headquarter Location

Gustaf Werners gata 2

Vastra Frolunda, 421 32,

Sweden

+46-31-721 80 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Vitrolife Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Vitrolife Rank

Latest Vitrolife News

Vitrolife publishes prospectus in connection with the admission to trading on Nasdaq Stockholm due to non-cash issue

Nov 26, 2021

News provided by Share this article Share this article GOTHENBURG, Sweden, Nov. 26, 2021 /PRNewswire/ -- Vitrolife AB (publ) ("Vitrolife") publishes a prospectus for the admission to trading of newly issued shares in Vitrolife on Nasdaq Stockholm's main market in connection with a non-cash issue through which Vitrolife acquires all shares in Mendel Holdco S.L. and thereby indirectly all shares in Igenomix S.L. The transaction is described in more detail in Vitrolife's press release dated 8 July 2021. The prospectus does not contain any offer to subscribe for, or in any other way acquire shares or other financial instruments in Vitrolife, either in Sweden or in any other jurisdiction. The transaction means that the number of shares in Vitrolife will increase by 17,251,312 shares from 118,195,878 shares to a total of 135,447,190 shares and that the share capital will increase by SEK 3,519,267.648, from SEK 24,111,959.112 to a total of SEK 27,631,226.760. The dilution for Vitrolife's existing shareholders amounts to 12.7 percent of capital and votes. The prospectus, that has been prepared in connection with the admission to trading of the newly issued shares, has today been approved and registered by the Swedish Financial Supervisory Authority ("Finansinspektionen"). The prospectus is available on Finansinspektionen's website, www.fi.se , and Vitrolife's website, www.vitrolife.com , as well as on request in paper format. Appendix: Prospectus (Swedish)

Vitrolife Investments

2 Investments

Vitrolife has made 2 investments. Their latest investment was in Cellartis as part of their Series A on May 5, 2003.

CBI Logo

Vitrolife Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/15/2003

Series A

Cellartis

$1.9M

No

Undisclosed Investors

1

9/17/2001

Seed

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/15/2003

9/17/2001

Round

Series A

Seed

Company

Cellartis

Subscribe to see more

Amount

$1.9M

$99M

New?

No

Subscribe to see more

Co-Investors

Undisclosed Investors

Sources

1

10

Vitrolife Portfolio Exits

1 Portfolio Exit

Vitrolife has 1 portfolio exit. Their latest portfolio exit was Cellartis on November 07, 2011.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/7/2011

Acquired

1

Date

11/7/2011

Exit

Acquired

Companies

Valuation

Acquirer

Sources

1

Vitrolife Acquisitions

4 Acquisitions

Vitrolife acquired 4 companies. Their latest acquisition was Igenomix on July 08, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/8/2021

Acq - Fin - II

$991

Acquired

6

11/5/2014

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

4/3/2013

Subscribe to see more

$99M

Subscribe to see more

10

10/5/2012

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

7/8/2021

11/5/2014

4/3/2013

10/5/2012

Investment Stage

Acq - Fin - II

Private Equity

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Total Funding

$99M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

6

10

10

10

Vitrolife Partners & Customers

2 Partners and customers

Vitrolife has 2 strategic partners and customers. Vitrolife recently partnered with Excellarate on July 7, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

7/26/2019

Partner

Excellarate

United States

Vitrolife - Collaboration agreement on Piezo technique for improved ICSI procedure

`` It has been interesting to follow the uptake of Piezo-ICSI in human Vitro Fertilisation especially in Japan and we are excited to partner with Prime Tech to take this technology to the global market '' , says Thomas Axelsson , CEO of Vitrolife .

1

4/11/2019

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/26/2019

4/11/2019

Type

Partner

Partner

Business Partner

Excellarate

Country

United States

Subscribe to see more

News Snippet

Vitrolife - Collaboration agreement on Piezo technique for improved ICSI procedure

`` It has been interesting to follow the uptake of Piezo-ICSI in human Vitro Fertilisation especially in Japan and we are excited to partner with Prime Tech to take this technology to the global market '' , says Thomas Axelsson , CEO of Vitrolife .

Subscribe to see more

Subscribe to see more

Sources

1

10

Vitrolife Service Providers

3 Service Providers

Vitrolife has 3 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Accounting Firm

Auditor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Subscribe to see more

Subscribe to see more

Provider Type

Accounting Firm

Subscribe to see more

Subscribe to see more

Service Type

Auditor

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Vitrolife Team

9 Team Members

Vitrolife has 9 team members, including current Chief Executive Officer, Thomas Axelsson.

Name

Work History

Title

Status

Thomas Axelsson

Chief Executive Officer

Current

Barry White

Chief Executive Officer

Current

Mikael Engblom

Chief Financial Officer

Current

Stefan Jacobsson

Chief Financial Officer

Current

Peter Svalander

Founder

Former

Name

Thomas Axelsson

Barry White

Mikael Engblom

Stefan Jacobsson

Peter Svalander

Work History

Title

Chief Executive Officer

Chief Executive Officer

Chief Financial Officer

Chief Financial Officer

Founder

Status

Current

Current

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.